# US 2023/0054997 A1 · Copper complexes for treatment of neurodegenerative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054997 A1
- Document ID: US20230054997A1
- Status: Published application
- Kind: A1
- Application number: 17/458,021
- Filed: 2021-08-26
- Published: 2023-02-23
- Earliest claimed: 2020-08-26
- Assignees: ALS Therapy Development Institute
- Applicants: ALS Therapy Development Institute
- Inventors: Matvey Lukashev; Alexei Pushechnikov; Peter Demin; Kyle DENTON
- Web page: https://patentgrep.com/patent/US20230054997A1

## CPC

- C07D 213/53: Nitrogen atoms
- C07F 1/08: Copper compounds
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/24: Oxygen or sulfur atoms
- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 265/28: 1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 307/81: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07F 9/5442: {Aromatic phosphonium compounds (P-C aromatic linkage)}
- C07F 9/6596: having atoms other than oxygen, sulfur, selenium, tellurium, nitrogen or phosphorus as ring hetero atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).

## Claims

### Claim 1

A compound of Formula (V):
or pharmaceutically acceptable salts thereof, wherein:
R1 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R2 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R3 is 4- to 8-membered heterocycle or 5-membered heteroaryl, wherein the 4- to 8-membered heterocycle is optionally substituted one, two, or three times with the group R3a, and wherein the 5-membered heteroaryl is optionally substituted one, two, or three times with the group R3b;
R3a independently for each occurrence is C1-C6 alkyl, C1-C6 alkyl-(C6-C10 aryl), C1-C6 alkyl-(5- to 10-membered heteroaryl), S(O)2H, S(O)2—(C1-C6 alkyl), S(O)2—(C3-C7 cycloalkyl), or S(O)2—(C6-C10 aryl); wherein each heteroaryl is optionally further substituted one to four times with C1-C6 alkyl or C6-C10 aryl; and wherein each C6-C10 aryl is optionally further substituted one to four times with C1-C6 alkyl;
R3b independently for each occurrence is C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkyl-N(R5)2, (C1-C6 alkyl)-O—(C1-C6 alkyl), halo, nitro, cyano, C6-C10 aryl, C(O)-(4- to 8-membered heterocycle), C1-C6 alkyl-(C6-C10 aryl), C1-C6 alkyl-(5- to 10-membered heteroaryl), or C1-C6 alkyl-(4- to 8-membered heterocycle), wherein each 4- to 8-membered heterocycle, C6-C10 aryl, and 5- to 10-membered heteroaryl are optionally further substituted one to four times with C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, or halo;
R4 is hydrogen or C1-3 alkyl; and
R5 independently for each occurrence is hydrogen, C1-C6 alkyl, or C1-C3 alkyl-(C6-C10 aryl).

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
R1 is methyl or ethyl; and
R2 is methyl or ethyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R3 is tetrahydrofuranyl, morpholinyl, piperidinyl, furyl, thiophenyl, pyrrolyl, oxazolyl, pyrazolyl, or imidazolyl, wherein the tetrahydrofuranyl, morpholinyl, and piperidinyl are optionally substituted one, two, or three times with the group R3a, and wherein the furyl, thiophenyl, pyrrolyl, oxazolyl, pyrazolyl, and imidazolyl are optionally substituted one, two, or three times with the group R3b.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R3 is furyl, thiophenyl, oxazolyl, pyrazolyl, or imidazolyl optionally substituted one, two, or three times with the group R3b.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein when R1 is not methyl, R2 is not methyl, and R4 is not hydrogen, then R3b independently for each occurrence is C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkyl-N(R5)2, (C1-C6 alkyl)-O—(C1-C6 alkyl), halo, nitro, cyano, C6-C10 aryl, C(O)-(4- to 8-membered heterocycle), C1-C6 alkyl-(C6-C10 aryl), C1-C6 alkyl-(5- to 10-membered heteroaryl), or C1-C6 alkyl-(4- to 8-membered heterocycle), wherein each 4- to 8-membered heterocycle, C6-C10 aryl, and 5- to 10-membered heteroaryl are optionally further substituted one or two times with C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, or halo.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound of claim 1, wherein R3b is selected from the group consisting of:

### Claim 10 (depends on 1)

The compound of claim 1, wherein R3 is furyl optionally substituted one time with C1-C3 alkyl-N(C1-C4 alkyl)2 or C1-C3 alkyl-(5- to 6-membered heterocycle), wherein the 5- to 6-membered heterocycle is optionally further substituted one to four times with C1-C3 alkyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R3 is thiophenyl, oxazolyl, pyrazolyl, or imidazolyl, optionally substituted one, two, or three times with C1-C6 alkyl, halo, C6-C10 aryl, or C1-C6 alkyl-(C6-C10 aryl), wherein each C6-C10 aryl is optionally further substituted one to four times with C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, or halo.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R3 is selected from the group consisting of:

### Claim 13 (depends on 1)

The compound of claim 1, wherein R4 is hydrogen or methyl.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The compound of claim 1, selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The compound of claim 15, selected from the group consisting of Compounds 25, 29, 32, 34, 41, 43, 44, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 90, 91, 94, 95, 96, 98, 100, 104, 105, 106, 120, and 123, or a pharmaceutically acceptable salt thereof.

### Claim 17

A compound of Formula (IV):
or pharmaceutically acceptable salts thereof, wherein:
L is C3-C7 cycloalkyl, C1-C6 alkyl, or absent;
R1 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R2 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R3 is C6-C10 aryl, 5- to 10-membered heteroaryl, C3-C1 cycloalkyl, C(O)NH—(C1-C6 alkyl)-PPh3, hydroxy, C1-C6 alkoxy, or O—(C1-C6 alkyl)-O—(C1-C6 alkyl), wherein the C6-C10 aryl is substituted one, two, or three times with the group R3a, and wherein the 5- to 10-membered heteroaryl is optionally substituted one, two, or three times with the group R3b;
R3a independently for each occurrence is C3-C7 cycloalkyl or 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally further substituted one, two, or three times with C1-C3 alkyl;
R3b independently for each occurrence is C1-C3 alkyl, C1-C3 alkoxy, C3-C7 cycloalkyl, or 4- to 8-membered heterocycle, wherein the heterocycle is optionally further substituted one, two, or three times with C1-C3 alkyl; and
R4 is hydrogen, C1-C3 alkyl, or C6-C10 aryl;
provided that when L is absent, R3 is C6-C10 aryl substituted one, two, or three times with the group R3a; or when L is absent, R3 is 6- to 10-membered heteroaryl substituted one, two, or three times with the group R3b; or when L is absent, R3 is 6- to 10-membered heteroaryl optionally substituted one, two, or three times with the group R3b, and R4 is H.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The compound of claim 17, wherein:
R1 is methyl or ethyl; and
R2 is methyl or ethyl.

### Claim 20 (depends on 17)

The compound of claim 17, wherein R3 is phenyl, pyrazolyl, pyridinyl, benzofuranyl, benzothiazolyl, benzodioxolyl, C3-C6 cycloalkyl, adamantyl, C(O)NH—(C1-C6 alkyl)-PPh3, hydroxy, C1-C6 alkoxy, or O—(C1-C6 alkyl)-O—(C1-C6 alkyl), wherein the phenyl is substituted one, two, or three times with the group R3a; and wherein the pyrazolyl, pyridinyl, benzofuranyl, benzothiazolyl, and benzodioxolyl are optionally substituted one, two, or three times with the group R3b.

### Claim 21

(canceled)

### Claim 22 (depends on 17)

The compound of claim 17, wherein when L is absent, R3 is C6-C10 aryl substituted one, two, or three times with the group R3a; or when L is absent, R3 is 6- to 10-membered heteroaryl substituted one, two, or three times with the group R3b.

### Claim 23 (depends on 17)

The compound of claim 17, selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

The compound of claim 23, selected from the group consisting of Compounds 2, 12, 15, 17, 59, 60, 61, 66, 74, and 77, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

The compound of claim 1, having a structure according to Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
L is C3-C7 cycloalkyl, C1-C6 alkyl, or absent
R1 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R2 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R3 is C6-C10 aryl, 5- to 10-membered heteroaryl, C(O)NH—(C1-C6 alkyl)-PPh3, hydroxy, C1-C6 alkoxy, or O—(C1-C6 alkyl)-O—(C1-C6 alkyl), wherein the C6-C10 aryl is substituted one, two, or three times with the group R3a, and wherein the 5- to 10-membered heteroaryl is optionally substituted one, two, or three times with the group R3b;
R3a independently for each occurrence is C3-C7 cycloalkyl or 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally further substituted one, two, or three times with C1-C3 alkyl;
R3b independently for each occurrence is C1-C3 alkoxy, C3-C7 cycloalkyl, or 4- to 8-membered heterocycle, wherein the heterocycle is optionally further substituted one, two, or three times with C1-C3 alkyl; and
R4 is hydrogen, C1-C3 alkyl, or C6-C10 aryl;
provided that when L is absent, R3 is C6-C10 aryl substituted one, two, or three times with the group R3a; or when L is absent, R3 is 6- to 10-membered heteroaryl substituted one, two, or three times with the group R3b.

### Claim at position 26

26-36. (canceled)

### Claim 37 (depends on 17)

The compound of claim 17, having a structure according to Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R2 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R3 is 4- to 8-membered heterocycle or 5-membered heteroaryl, wherein the 4- to 8-membered heterocycle is optionally substituted one, two, or three times with the group R3a, and wherein the 5-membered heteroaryl is optionally substituted one, two, or three times with the group R3b;
R3a independently for each occurrence is C1-C6 alkyl, C1-C6 alkyl-(C6-C10 aryl), S(O)2H, S(O)2—(C1-C6 alkyl), S(O)2—(C3-C7 cycloalkyl), or S(O)2—(C6-C10 aryl);
R3b independently for each occurrence is C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, halo, nitro, cyano, C(O)-(4- to 8-membered heterocycle), or C1-C6 alkyl-(4- to 8-membered heterocycle), wherein each 4- to 8-membered heterocycle is optionally further substituted one, two, or three times with C1-C3 alkyl; and
R4 is hydrogen or C1-3 alkyl.

### Claim at position 28

38-47. (canceled)

### Claim 48

A compound of Formula (III):
or a pharmaceutically acceptable salt thereof, wherein:
L is C1-C6 alkyl or absent
R1 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R2 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R3 is C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, halo, hydroxy, C(O)NH2, C(O)NH(C1-C6 alkyl), C(O)N(C1-C6 alkyl)2, or C(O)-(4- to 8-membered heterocycle), wherein the C1-C6 alkyl and the C1-C6 alkoxy are optionally substituted one, two, or three times with C6-C10 aryl, and wherein the C(O)-(4- to 8-membered heterocycle) is optionally substituted one, two, or three times with C1-C3 alkyl.

### Claim at position 30

49-54. (canceled)

### Claim 55 (depends on 48)

The compound of claim 48, selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim at position 32

56-58. (canceled)

### Claim 59 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, diluent, or carrier.

### Claim 60 (depends on 1)

A method of treating or preventing a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

### Claim 61 (depends on 60)

The method of claim 60, wherein the neurodegenerative disease is amyotrophic lateral sclerosis (ALS), frontal temporal dementia (FTD), Parkinson's disease, Huntington's disease, and Alzheimer's disease.

### Claim at position 36

62-68. (canceled)

### Claim 69

A method of making a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
L is C3-C7 cycloalkyl, C1-C6 alkyl, or absent
R1 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R2 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R3 is C6-C10 aryl, 5- to 10-membered heteroaryl, C(O)NH—(C1-C6 alkyl)-PPh3, hydroxy, C1-C6 alkoxy, or O—(C1-C6 alkyl)-O—(C1-C6 alkyl), wherein the C6-C10 aryl is substituted one, two, or three times with the group R3a, and wherein the 5- to 10-membered heteroaryl is optionally substituted one, two, or three times with the group R3b;
R3a independently for each occurrence is C3-C7 cycloalkyl or 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally further substituted one, two, or three times with C1-C3 alkyl;
R3b independently for each occurrence is C1-C3 alkoxy, C3-C7 cycloalkyl, or 4- to 8-membered heterocycle, wherein the heterocycle is optionally further substituted one, two, or three times with C1-C3 alkyl; and
R4 is hydrogen, C1-C3 alkyl, or C6-C10 aryl;
provided that when L is absent, R3 is C6-C10 aryl substituted one, two, or three times with the group R3a; or when L is absent, R3 is 6- to 10-membered heteroaryl substituted one, two, or three times with the group R3b;
the method comprising mixing a compound of Formula (I-A):
with a copper (II) salt to form the compound of Formula (I).

### Claim at position 38

70-76. (canceled)

### Claim 77 (depends on 17)

A pharmaceutical composition comprising a compound of claim 17, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, diluent, or carrier.

### Claim 78 (depends on 17)

A method of treating or preventing a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 17.

### Claim 79 (depends on 48)

A pharmaceutical composition comprising a compound of claim 48, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, diluent, or carrier.

### Claim 80 (depends on 48)

A method of treating or preventing a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 48.
